Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
China's National Medical Products Administration (NMPA)
Pharma
Eisai, ex-NMPA official, Pfizer-Summit—Fierce Pharma Asia
Eisai initiated a U.S. restructuring program. A former China NMPA deputy director is under investigation. Pfizer formed a collaboration with Summit.
Angus Liu
Feb 28, 2025 8:45am
Kelun's Merck-partnered TROP2 ADC snags first nod in China
Nov 27, 2024 10:56am
Dr. Reddy's hit with ban from China's drug procurement program
Sep 3, 2024 3:56pm
Eli Lilly partner Hutchmed scraps stomach cancer filing
Aug 30, 2024 10:39am
Daewoong Bio banned from China drug procurement program
Jul 19, 2024 10:21am
China signs off on Novo Nordisk's obesity treatment Wegovy
Jun 25, 2024 10:12am
